TNF and bacterial arthritis: BSRBR reported that the risk of septic arthritis with specific anti-TNF were etanercept HR 2.3 (CI = 1.2-4.4), infliximab HR 1.6 (CI = 0.8-3.2), and adalimumab HR 1.8 (CI = 1.0-3.5).